Offering Adds $67.5M More for Optimer's Fidaxomicin
By Tom Wall
Monday, February 14, 2011
Optimer Pharmaceuticals Inc. continued to take care of its near-term cash needs in anticipation of a commercial launch of Clostridium difficile infection (CDI) drug fidaxomicin by raising gross proceeds of $67.5 million in an underwritten public offering of 6 million shares of common stock priced at $11.25 per share, about 10.5 percent below the previous day's closing price.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.